Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL2167530 | 0.99 | CHRM2 (0.60) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL27974717 | 0.99 | CHRM2 (0.60) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL29400593 | 0.99 | CHRM2 (0.60) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL2169666 | 0.97 | CHRM2 (0.64) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL28223580 | 0.97 | CHRM2 (0.64) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL2166848 | 0.96 | CHRM2 (0.63) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL4231044 | 0.96 | CHRM2 (0.63) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL28250221 | 0.96 | CHRM2 (0.63) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Ipratropium SCHEMBL28250222 | 0.96 | CHRM2 (0.65) | CHRM2CHRM5MEN1KMT2ACHRM4 | |
| Atropine SCHEMBL5079571 | 0.87 | MAPT (0.64) | CHRM2CHRM5MEN1KMT2ACHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2335731-A2 | Multiple-variable dose regimen for treating TNF-alpha-related disorders | Abbott Biotechnology Ltd (BM) | 2011-06-22 | — | — | EP | claimed |
| US-20240209369-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240175017-A1 | COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-05-30 | — | — | US | disclosed |
| EP-4365291-A2 | COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240132886-A1 | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-3849987-B1 | TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2024-04-17 | — | — | EP | disclosed |
| EP-4342543-A2 | TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11873491-B2 | Complement component C5 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-1685152-A2 | IL-18 BINDING PROTEINS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| US-20060009385-A1 | Multiple-variable dose regimen for treating TNFalpha-related disorders | ABBOTT BIOTECHNOLOGY LTD. (BM) | 2006-01-12 | — | — | US | disclosed |
| WO-2005110452-A2 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS | ABBOTT BIOTECHNOLOGY LTD. (BM) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050147610-A1 | IL-18 binding proteins | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005047307-A2 | IL-18 BINDING PROTEINS | ABBOTT LABORATORIES (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050100965-A1 | IL-18 binding proteins | ABBOTT LABORATORIES | 2005-05-12 | — | — | US | disclosed |
| US-20040131614-A1 | Tumor necrosis factor antibodies neutralization | ABBOTT BIOTECHNOLOGY LTD. (BM) | 2004-07-08 | — | — | US | disclosed |
| US-20040126372-A1 | Administering antibodies; respiratory system disorders; cardiovascular disorders; metabolism disorders; anemia; analgesics; liver disorders; skin disorders | ABBOTT BIOTECHNOLOGY LTD. (BM) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132886-A1 | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | C9, HNRNPH3, HNRNPA0 | CHRM3 4874/4885CHRM2 4879/4885CHRM5 4866/4885 |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | CHRM3 4871/4885CHRM2 4882/4885CHRM5 4884/4885 |
| US-11873491-B2 | Complement component C5 iRNA compositions and methods of use thereof | C5, RNASEH1, RNASEL | CHRM3 4835/4885CHRM2 4797/4885CHRM5 4474/4885 |
| US-20240175017-A1 | COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | C5, RNASEH1, RNASEL | CHRM3 4835/4885CHRM2 4797/4885CHRM5 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.